<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00062023</url>
  </required_header>
  <id_info>
    <org_study_id>ID01-454</org_study_id>
    <secondary_id>P30CA016672</secondary_id>
    <secondary_id>MDA-ID-01454</secondary_id>
    <secondary_id>CDR0000304433</secondary_id>
    <nct_id>NCT00062023</nct_id>
  </id_info>
  <brief_title>Comparison of Sulindac, Aspirin, and Ursodiol in Preventing Colorectal Cancer</brief_title>
  <official_title>Phase II Study Of Colorectal ACF Screening, Regression And Prevention In High Risk Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the&#xD;
      development or recurrence of cancer. It is not yet known whether sulindac, aspirin, or&#xD;
      ursodiol is more effective in preventing colorectal cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying how well sulindac works compared to&#xD;
      aspirin or ursodiol in preventing colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the percentage change in colorectal aberrant crypt foci (ACF) in patients with&#xD;
           a history of colorectal cancer or at high risk for colorectal cancer when treated with&#xD;
           sulindac vs aspirin vs ursodiol.&#xD;
&#xD;
        -  Determine the safety and efficacy of these drugs, in terms of ability to cause&#xD;
           regression of existing colorectal ACF and prevent new ACF development, in these&#xD;
           patients.&#xD;
&#xD;
      OUTLINE: This is a partially blinded, randomized, placebo-controlled study. Patients are&#xD;
      stratified according to colorectal neoplasia (adenoma vs carcinoma). Patients are randomized&#xD;
      to 1 of 4 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive oral sulindac twice daily.&#xD;
&#xD;
        -  Arm II: Patients receive oral aspirin once daily.&#xD;
&#xD;
        -  Arm III: Patients receive oral ursodiol three times daily.&#xD;
&#xD;
        -  Arm IV: Patients receive oral sulindac placebo twice daily. In all arms, treatment&#xD;
           continues for 12 months in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients undergo a colonoscopy at baseline and at the end of treatment.&#xD;
&#xD;
      Patients are followed at 2 months after the end of treatment.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 172 patients (43 per treatment arm) with a history of&#xD;
      colorectal cancer or adenomas will be accrued for this study. A total of 20 additional&#xD;
      patients with no elevated risk of colorectal neoplasia will be accrued, but not randomized,&#xD;
      for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study closed by the NCI.&#xD;
  </why_stopped>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">May 2006</completion_date>
  <primary_completion_date type="Actual">April 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage Change in Colorectal ACF Patients Treated with Sulindac, Aspirin or Ursodiol</measure>
    <time_frame>12 Months</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I Sulindac</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral sulindac twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II Aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral aspirin once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III Ursodiol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral ursodiol three times daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm IV: Sulindac Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral sulindac placebo twice daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetylsalicylic acid (Aspirin)</intervention_name>
    <description>Patients receive oral aspirin once daily for 12 months.</description>
    <arm_group_label>Arm II Aspirin</arm_group_label>
    <other_name>Aspirin</other_name>
    <other_name>USAN</other_name>
    <other_name>ASA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulindac</intervention_name>
    <description>Patients receive oral sulindac twice daily for 12 months.</description>
    <arm_group_label>Arm I Sulindac</arm_group_label>
    <other_name>Clinoril</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ursodiol</intervention_name>
    <description>Patients receive oral ursodiol three times daily for 12 months.</description>
    <arm_group_label>Arm III Ursodiol</arm_group_label>
    <other_name>ursodeoxycholic acid</other_name>
    <other_name>UDCA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sulindac Placebo</intervention_name>
    <description>Oral sulindac placebo twice daily.</description>
    <arm_group_label>Arm IV: Sulindac Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subjects, age 40-80 years&#xD;
&#xD;
          2. with &gt;5 colorectal ACF and a prior history of colorectal cancer defined as Dukes A/B1&#xD;
             carcinoma within 5 years of entry or any stage of colorectal cancer if at least 5&#xD;
             years post surgical resection (86 subjects)&#xD;
&#xD;
          3. with &gt;5 colorectal ACF and recent/current history of colorectal adenoma(s) defined as&#xD;
             one of the following: one adenomatous polyp &gt;1cm or two or more adenomatous polyps of&#xD;
             any size or one adenomatous polyp of any size and a documented history of adenomatous&#xD;
             polyp(s) (86 subjects)&#xD;
&#xD;
          4. No elevated risk of colorectal cancer or adenomas (20 subjects)&#xD;
&#xD;
          5. Subjects will be permitted to use Nasonex but all other nasal steroids are prohibited.&#xD;
             Subjects may change to Nasonex but must have discontinued previous nasal steroid use&#xD;
             for at least 30 days prior to study randomization.&#xD;
&#xD;
          6. If participant is female and of childbearing potential, she must agree to use adequate&#xD;
             contraception and must have a negative serum pregnancy test within 14 days prior to&#xD;
             study drug administration&#xD;
&#xD;
          7. No use of investigational agent(s) within the last 3 months or at the discretion of&#xD;
             the medical monitor&#xD;
&#xD;
          8. The subject will be allowed to proceed to randomization so long as all of the&#xD;
             following laboratory criteria are met on baseline evaluation: Hgb &gt; 10.0 g/dl,&#xD;
             platelet count &gt; 100,000/ul; WBC &gt; 3,000/ul; ALT &lt; 2 x upper limit of normal; AST &lt; 2&#xD;
             x upper limit of normal, and total bilirubin &lt;1.5mg/100ml.&#xD;
&#xD;
          9. Patients requiring use of hormone modulators such as Tamoxifen or Arimidex will be&#xD;
             permitted to enroll providing they meet all of the eligibility criteria noted above&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known diagnosis of FAP, hereditary non-polyposis colon cancer (HNPCC), or inflammatory&#xD;
             bowel disease&#xD;
&#xD;
          2. History of hypersensitivity to COX-2 inhibitors, sulfonamides, NSAIDs , salicylates,&#xD;
             or ursodeoxycholic acid&#xD;
&#xD;
          3. Use of NSAIDs, including aspirin, at any dose during the six months prior to study&#xD;
             entry will require a three month washout period prior to eligibility beginning with&#xD;
             the time of the last dose. Participants must be off all NSAIDs for three months prior&#xD;
             to study entry. Individuals on cardioprotectant aspirin at any dose will not be&#xD;
             eligible.&#xD;
&#xD;
          4. History of gastroduodenal ulcers documented endoscopically would preclude a patient&#xD;
             from participation in the trial&#xD;
&#xD;
          5. Known inability to participate in the scheduled follow-up tests.&#xD;
&#xD;
          6. Significant medical or psychiatric problems which would make the patient a poor&#xD;
             protocol candidate, in the opinion of the principal investigator.&#xD;
&#xD;
          7. &quot;Unacceptable clinical risk&quot; to proceed (based upon the subclinical discoveries made&#xD;
             via baseline colonoscopy and biopsies).&#xD;
&#xD;
          8. Patient has undergone a total colectomy&#xD;
&#xD;
          9. Patient has received chemotherapy within the past 6 months of randomization into&#xD;
             study. Topical chemotherapy will be assessed on a case-by-case basis. Any history of&#xD;
             pelvic or rectal radiation therapy will exclude a patient from participating.&#xD;
&#xD;
         10. History of invasive carcinoma in the past five years (except patients with Dukes A/B1&#xD;
             carcinoma within 5 years of entry or any stage of colorectal cancer if at least 5&#xD;
             years post surgical resection)&#xD;
&#xD;
         11. Patients with rectal cancer are excluded except for transanal excision without&#xD;
             radiation.&#xD;
&#xD;
         12. Patients with acute liver disease, unexplained transaminase elevations or a history of&#xD;
             renal stones would be excluded.&#xD;
&#xD;
         13. Participants will not be permitted to be randomized into the trial if any of the&#xD;
             following laboratory values are reported at baseline : Hgb &lt; 10.0 g/dl, platelet count&#xD;
             &lt;100,000/ul; WBC &lt; 3,000/ul; ALT &gt; 2 x upper limit of normal; AST &gt; 2 x upper limit of&#xD;
             normal, and total bilirubin &gt;1.5mg/100ml.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert S. Bresalier, MD</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M.D. Anderson Cancer Center at University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>June 5, 2003</study_first_submitted>
  <study_first_submitted_qc>June 5, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2003</study_first_posted>
  <last_update_submitted>July 27, 2012</last_update_submitted>
  <last_update_submitted_qc>July 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>colorectal cancer</keyword>
  <keyword>stage I colon cancer</keyword>
  <keyword>stage II colon cancer</keyword>
  <keyword>stage III colon cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Sulindac</mesh_term>
    <mesh_term>Ursodeoxycholic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

